Intentar ORO - Gratis
Miran’ monetary policy advocacy is simply puzzling
Mint Mumbai
|September 25, 2025
Through one of the strangest twists in economic history, Stephen Miran, chief economic advisor to US President Donald Trump and newly appointed member of the Federal Reserve's board of governors, hasseen his career resurrected in almost mythical fashion ever since the failure ofthe investment firm he co-founded in 2022.
That company, Amberwave Partners, launched an ETF that “never attracted more than $1.7 million in assets” (a trifling sum in the world of US money management), according to The Wall Street Journal. Amberwave morphed into a hedge fund but didn’t gain traction and shut in late 2023.
Scarcely a year later, Trump’s victory in the US election amounted to a rebirth for Miran. Apart from being among the most ardent ofall the president’s yes-men, he isa vocal proponent of drastically curbing immigration, weakening the dollarand asking US allies to bear a larger share of defence expenses on strategic alliances. Trump’swin paved the way for him to take up a much larger roleas chair of the US Council of Economic Advisers. Last week, the 42-year-old economist, newly appointed to the Fed by a slim Senate margin, with every Democratic senator having voted against his appointment, cast the lone dissenting vote in the Fed’smonetary policy decision. He wanted a 50-basis-point cut to the Fed's federal funds target, twice the size of what was delivered. On Monday, Miran doubled down, arguing that the US economy needsaggressive cutsso the policy rate reaches about 2.5%.
Esta historia es de la edición September 25, 2025 de Mint Mumbai.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Mint Mumbai
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size

